ISSN:
1573-0646
Keywords:
SM-5887
;
Phase I
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary SM-5887, a new totally synthetic anthracycline derivative was studied in a phase I setting. Twenty-nine evaluable courses of treatment were conducted in groups at doses increasing from 10 to 130 mg/m2. Myelosuppression was the dose-limiting toxicity and a MTD was 130 mg/m2. At 130 mg/m2 the median lowest white blood cell count was 0.7 × 103/cmm (range: 0.3–1.8) and the median lowest granulocyte count was 0.1 × 103/cmm (range: 0–0.7) and the median lowest platelet count was 57 × l03/cmm (range: 4–176). Nonhematologic side effects were mild gastrointestinal symptoms and hair loss. The recommended dose and schedule for phase II setting is 100 mg/m2 every 3 weeks.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00170860
Permalink